{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:30:21Z","timestamp":1788201021779,"version":"build-2803163510"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222506\/Z\/21\/Z"],"award-info":[{"award-number":["222506\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Substandard and falsified (SF) medicines are a neglected public health threat, with an estimated 7% of antimicrobials in low- and middle-income countries being SF. However, quantifying their clinical impact remains challenging. We developed a general framework for estimating population-level impacts of SF antimicrobials on patient outcomes and apply it to SF fluoroquinolones in typhoid treatment. The framework combines two data sources: published surveys of antimicrobial quality to characterize the distribution of active pharmaceutical ingredient (API) content and individual-level patient data to estimate dose-response relationships. These are synthesized to evaluate population-level impacts. We extracted data from surveys of fluoroquinolone quality and fitted generalized additive models to data from seven clinical trials to estimate the causal effect of ofloxacin dose on typhoid outcomes. Application to typhoid demonstrated that while dose had negligible overall effect within trial dose ranges, lower doses worsened outcomes for non-susceptible strains. When the minimum inhibitory concentration was 1 mg\/L, ofloxacin matching observed ofloxacin quality (mean %API\u2009=\u2009102.8%) improved fever clearance by 4.1 hours (90% CrI: 0.75\u20138.7) compared to 100% API. At the same minimum inhibitory concentration, ofloxacin whose %API instead matched the ciprofloxacin surveys (mean %API\u2009=\u200993.6%) worsened fever clearance by 11 hours (90% CrI: 1.9\u201325). This framework can quantify the impact of SF antimicrobials on different pathogen\u2013antimicrobial pairs. For typhoid, it demonstrates that SF fluoroquinolones likely have a substantial impact on treatment outcomes in settings like South Asia where non-susceptible strains are prevalent. Increased vigilance around antimicrobial quality is important in such settings.<\/jats:p>","DOI":"10.1371\/journal.pgph.0007207","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:49:43Z","timestamp":1788198583000},"page":"e0007207","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: Application to typhoid fever"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-797X","authenticated-orcid":true,"given":"Sean","family":"Cavany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-347X","authenticated-orcid":true,"given":"Lawrence","family":"Adipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-7575","authenticated-orcid":true,"given":"Kerlijn","family":"van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Caillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Dolecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Hauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Nanyonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Stoesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben S.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"pgph.0007207.ref001","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102883","article-title":"The global burden of enteric fever, 2017\u20132021: a systematic analysis from the global burden of disease study 2021","volume":"77","author":"D Piovani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"pgph.0007207.ref002","volume-title":"The WHO AWaRe (Access, Watch, Reserve) antibiotic book","year":"2022","edition":"1"},{"key":"pgph.0007207.ref003","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/B978-1-4160-4390-4.00069-2","article-title":"Typhoid and Paratyphoid (Enteric) Fever","author":"JB Harris","year":"2013","journal-title":"Hunter\u2019s Tropical Medicine and Emerging Infectious Disease. Elsevier"},{"issue":"11","key":"pgph.0007207.ref004","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/cid\/cix185","article-title":"Treatment response in enteric fever in an era of increasing antimicrobial resistance: an individual patient data analysis of 2092 participants enrolled into 4 randomized, controlled trials in Nepal","volume":"64","author":"CN Thompson","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pgph.0007207.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001163","article-title":"The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy","volume":"5","author":"CM Parry","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"pgph.0007207.ref006","volume-title":"A study on the public health and socioeconomic impact of substandard and falsified medical products","author":"World Health Organization","year":"2017"},{"key":"pgph.0007207.ref007","unstructured":"Al-Kuwari DHM. Seventieth World Health Assembly: Provisional Summary Record of the Tenth Meeting. 2017."},{"key":"pgph.0007207.ref008","volume-title":"WHO global surveillance and monitoring system for substandard and falsified medical products","author":"World Health Organization","year":"2017"},{"key":"pgph.0007207.ref009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4269\/ajtmh.14-0725","article-title":"Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa","volume":"92","author":"JP Renschler","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"pgph.0007207.ref010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1475-2875-13-139","article-title":"Mind the gaps--the epidemiology of poor-quality anti-malarials in the malarious world--analysis of the WorldWide Antimalarial Resistance Network database","volume":"13","author":"P Tabernero","year":"2014","journal-title":"Malar J"},{"issue":"3","key":"pgph.0007207.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000052","article-title":"Guidelines for field surveys of the quality of medicines: a proposal","volume":"6","author":"PN Newton","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"pgph.0007207.ref012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1179\/146532805X23308","article-title":"Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children","volume":"25","author":"H Vinh","year":"2005","journal-title":"Ann Trop Paediatr"},{"issue":"4","key":"pgph.0007207.ref013","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.40.4.958","article-title":"Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children","volume":"40","author":"H Vinh","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pgph.0007207.ref014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00006454-199903000-00007","article-title":"A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children","volume":"18","author":"CXT Phuong","year":"1999","journal-title":"The Pediatric Infectious Disease Journal"},{"issue":"3","key":"pgph.0007207.ref015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1128\/AAC.00447-06","article-title":"Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever","volume":"51","author":"CM Parry","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pgph.0007207.ref016","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1128\/AAC.38.8.1716","article-title":"Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever","volume":"38","author":"MD Smith","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pgph.0007207.ref017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0035-9203(97)90102-4","article-title":"Short courses of ofloxacin for the treatment of enteric fever","volume":"91","author":"TC Nguyen","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7","key":"pgph.0007207.ref018","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1128\/AAC.44.7.1855-1859.2000","article-title":"A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever","volume":"44","author":"NT Chinh","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"pgph.0007207.ref019","unstructured":"Medicinal forms | Ofloxacin | Drugs | BNF content published by NICE. https:\/\/bnf.nice.org.uk\/drugs\/ofloxacin\/medicinal-forms\/. Accessed 2025 March 17."},{"issue":"6","key":"pgph.0007207.ref020","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package \u201cdagitty\u201d","volume":"45","author":"J Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"pgph.0007207.ref021","volume-title":"R Core Team. R: A Language and Environment for Statistical Computing","year":"2018"},{"key":"pgph.0007207.ref022","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v080.i01","article-title":"brms: An R Package for Bayesian Multilevel Models Using Stan","volume":"80","author":"PC B\u00fcrkner","year":"2017","journal-title":"J Stat Soft"},{"key":"pgph.0007207.ref023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.32614\/RJ-2018-017","article-title":"Advanced bayesian multilevel modeling with the R package brms","volume":"10","author":"PC B\u00fcrkner","year":"2018","journal-title":"The R Journal"},{"issue":"5","key":"pgph.0007207.ref024","article-title":"Bayesian item response modeling in R with brms and stan","volume":"100","author":"P-C B\u00fcrkner","year":"2021","journal-title":"J Stat Soft"},{"issue":"2","key":"pgph.0007207.ref025","first-page":"756","article-title":"An introduction to g methods","volume":"46","author":"AI Naimi","year":"2017","journal-title":"Int J Epidemiol"},{"key":"pgph.0007207.ref026","unstructured":"World Health Organization. The International Pharmacopoeia. 12 ed. 2025."},{"key":"pgph.0007207.ref027","author":"HF Ononna","year":"2017"},{"issue":"6","key":"pgph.0007207.ref028","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/jac\/dkab435","article-title":"A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR","volume":"77","author":"P Tabernero","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"pgph.0007207.ref029","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3109\/03639045.2011.628678","article-title":"Comparative evaluation of pharmaceutical products obtained in Mexico: augmenting existing scientific data","volume":"38","author":"KL Karlage","year":"2012","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"pgph.0007207.ref030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4314\/ijs.v20i1.16","article-title":"Quality assessment of ciprofloxacin tablets obtained from community pharmacies in Lagos, Nigeria","volume":"20","author":"AE Joda","year":"2018","journal-title":"Ife Journal of Science"},{"key":"pgph.0007207.ref031","doi-asserted-by":"crossref","first-page":"1494957","DOI":"10.1155\/2018\/1494957","article-title":"Quality Assessment of Some Essential Children\u2019s Medicines Sold in Licensed Outlets in Ashanti Region, Ghana","volume":"2018","author":"G Frimpong","year":"2018","journal-title":"J Trop Med"},{"issue":"2","key":"pgph.0007207.ref032","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1741134320921929","article-title":"In vitro quality evaluation of generic ciprofloxacin tablets available in community pharmacies of Dessie town, Northeast Ethiopia","volume":"21","author":"HK Desta","year":"2020","journal-title":"Journal of Generic Medicines"},{"issue":"2","key":"pgph.0007207.ref033","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4269\/ajtmh.20-0184","article-title":"Substandard and Falsified Antibiotics and Medicines against Noncommunicable Diseases in Western Cameroon and Northeastern Democratic Republic of Congo","volume":"103","author":"S Sch\u00e4fermann","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"pgph.0007207.ref034","article-title":"Fluoroquinolone resistance in Salmonella: insights by whole-genome sequencing","volume":"4","author":"WL Cuypers","year":"2018","journal-title":"Microb Genom"},{"issue":"1","key":"pgph.0007207.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1443-1","article-title":"Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis","volume":"18","author":"AJ Browne","year":"2020","journal-title":"BMC Med"},{"issue":"7","key":"pgph.0007207.ref036","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.trstmh.2003.10.014","article-title":"The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam","volume":"98","author":"CM Parry","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pgph.0007207.ref037","article-title":"Quality assurance of drugs used in clinical trials: proposal for adapting guidelines","volume":"350","author":"PN Newton","year":"2015","journal-title":"BMJ"},{"key":"pgph.0007207.ref038","unstructured":"WHO urges action to protect children from contaminated medicines. https:\/\/www.who.int\/news\/item\/23-01-2023-who-urges-action-to-protect-children-from-contaminated-medicines. Accessed 2025 March 31."},{"key":"pgph.0007207.ref039","unstructured":"Pisani E. Antimicrobial resistance: What does medicine quality have to do with it? Review on Antimicrobial Resistance. 2015. https:\/\/amr-review.org\/sites\/default\/files\/ElizabethPisaniMedicinesQualitypaper.pdf"},{"key":"pgph.0007207.ref040","author":"SM Cavany","year":"2021"},{"issue":"6","key":"pgph.0007207.ref041","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archinte.1946.00220060002001","article-title":"Typhoid; clinical analysis of 360 cases","volume":"78","author":"BM Stuart","year":"1946","journal-title":"Arch Intern Med (Chic)"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0007207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:49:51Z","timestamp":1788198591000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0007207"}},"subtitle":[],"editor":[{"given":"Kiatichai","family":"Faksri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0007207","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}